Literature DB >> 11905951

Femoral vessel injuries.

Eddy H Carrillo1, David A Spain, Frank B Miller, J David Richardson.   

Abstract

Early diagnosis, expeditious vascular repair, and aggressive management of complications have resulted in an amputation rate of less than 9%. Repair rather than ligation of an associated femoral vein injury is commonly practiced by experienced trauma surgeons. In most circumstances, a reversed autogenous saphenous vein graft from the contralateral extremity is the conduit of choice; however, if a saphenous vein cannot be used because of size discrepancies, multiple associated trauma, or extensive contamination, polytetrafluoroethylene can be used with good results. If vein ligation is performed, early fasciotomy is indicated for close and meticulous monitoring of the compartmental pressures. Clearly, the most crucial components for a successful outcome are a thorough evaluation, early operation, and a flawless vascular repair.

Entities:  

Mesh:

Year:  2002        PMID: 11905951     DOI: 10.1016/S0039-6109(03)00140-3

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  3 in total

1.  Acute traumatic superficial femoral arterial laceration findings on computed tomographic angiography: A case report.

Authors:  Shinsuke Takeda; Masahiro Tatebe; Yoshine Mori; Kenji Tanaka; Akihiko Tabuchi; Hitoshi Hirata
Journal:  Radiol Case Rep       Date:  2018-04-11

2.  Risk Factors of Amputation in Lower Extremity Trauma with Combined Femoropopliteal Arterial Injury.

Authors:  JeaHwan Kim; Yong Sun Jeon; Soon Gu Cho; Kee Chun Hong; Keun-Myoung Park
Journal:  Vasc Specialist Int       Date:  2019-03

3.  Hemodynamic Instability after Low-Energy Thigh Contusion Caused by Injury to the Femoral Artery: A Case Report and Literature Review.

Authors:  Juan Miguel Rodríguez-Roiz; José Ballesteros-Betancourt; Raquel García-Tarriño; Victor Antonio Rodríguez-Roiz; Manuel Llusa
Journal:  Case Rep Orthop       Date:  2016-05-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.